Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.24.3
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 142,050 $ 153,290
Short-term restricted cash 80 160
Short-term equity securities 785 161
Trade and other receivables, net 1,045 1,004
Short-term royalty and commercial payment receivables 12,682 14,215
Prepaid expenses and other current assets 2,379 483
Total current assets 159,021 169,313
Long-term restricted cash 4,686 6,100
Property and equipment, net 34 25
Operating lease right-of-use assets 335 378
Long-term royalty and commercial payment receivables 54,207 57,952
Exarafenib milestone asset (Note 4) 3,125  
Other assets - long term 1,932 533
Total assets 223,340 234,301
Current liabilities:    
Accounts payable 1,131 653
Accrued and other liabilities 2,451 2,768
Contingent consideration under RPAs, AAAs and CPPAs 4,000 7,000
Operating lease liabilities 434 54
Unearned revenue recognized under units-of-revenue method 1,924 2,113
Preferred stock dividend accrual 1,368 1,368
Current portion of long-term debt 9,826 5,543
Total current liabilities 21,134 19,499
Unearned revenue recognized under units-of-revenue method - long-term 5,589 7,228
Exarafenib milestone contingent consideration (Note 4) 3,125  
Long-term operating lease liabilities 594 335
Long-term debt 108,089 118,518
Total liabilities 138,531 145,580
Commitments and Contingencies (Note 10)
Stockholders' equity:    
Common stock, $0.0075 par value, 277,333,332 shares authorized, 11,755,223 and 11,495,492 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 88 86
Additional paid-in capital 1,317,657 1,311,809
Accumulated other comprehensive income 104  
Accumulated deficit (1,233,089) (1,223,223)
Total stockholders' equity 84,809 88,721
Total liabilities and stockholders' equity 223,340 234,301
8.625% Series A Cumulative, Perpetual Preferred Stock    
Stockholders' equity:    
Preferred Stock 49 49
8.375% Series B Cumulative, Perpetual Preferred Stock    
Stockholders' equity:    
Preferred Stock
Convertible preferred stock    
Stockholders' equity:    
Preferred Stock